Amgen initiated with a Hold at Jefferies

Jefferies initiated coverage of Amgen (AMGN) with a Hold rating and $350 price target With the stock having run up about 35% over the past six months, driven by excellent near-term commercial execution, removal of regulatory overhangs and the macro environment, the firm thinks the stock looks fairly valued at current levels, the analyst tells investors.